ミカファンギンの血漿中濃度推移と有効性および安全性について

概要

論文の詳細を見る
We administered micafungin (MCFG) to 10 patients who were admitted to Sapporo City General Hospital with suspected deep invasive fungal infections, and evaluated (1) the relationship between peak and trough plasma concentrations of MCFG and the dose, (2) the effects of hepatic and renal dysfunction on plasma concentrations and (3) their efficacy and safety. Plasma MCFG levels were measured by high performance liquid chromatography. The efficacy of MCFG was evaluated on the basis of the results of a mycological serologic test and a culture test, and safety on the basis of liver function, kidney function, and presence or absence of blood disorders. The volume of distribution was 0.337±0.099 L/kg, the half-life was 12.21±3.16 hr, and clearance was 1.076±0.442 L/hr. There was a positive correlation between the dose per body weight and peak/trough plasma concentrations. Neither liver nor kidney dysfunction influenced the plasma concentration of MCFG. In 5 patients with candidiasis, 1 patient with aspergillosis, and 2 patients with mycosis (diagnosis was unclear), the administration of MCFG relieved symptoms, and these patients were regarded as responders. In 4 (10 episodes) of 9 patients in whom the safety of MCFG could be evaluated, there were adverse events, for which it was unknown whether there was a relationship with MCFG or not, suggesting the necessity of careful clinical laboratory test monitoring during MCFG dosing. Our results suggest that MCFG was a useful antifungal agent since its plasma concentrations were not affected by liver or kidney dysfunction and demonstrated good efficacy.
日本医療薬学会の論文
2007-07-10

ミカファンギンの血漿中濃度推移と有効性および安全性について

スポンサーリンク

概要

著者

関連論文

スポンサーリンク